CLINICAL AND PATHOGENETIC FEATURES OF INFLAMMATORY BOWEL DISEASES: A LITERATURE REVIEW Aigerim B. Japparkulova1, https://orcid.org/0009-0006-8841-2051
Background & Aims: Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, pose significant challenges and are associated with a rising global incidence. However, research in Kazakhstan is limited and primarily descriptive. This review aims to elucidate the clinical and pathogenetic features of IBD in Kazakhstan to improve diagnostic and therapeutic approaches. A systematic review was conducted to identify common associations.
Objectives: To evaluate the clinical and pathogenetic features of inflammatory bowel diseases in Kazakhstan and their implications for diagnosis and treatment.
Methods: We analyzed systematic reviews and studies published in PubMed, Scopus, MEDLINE, EMBASE, and Cochrane databases from 2014 to the present. This review specifically examined approximately 60 articles from the past decade, focusing on IBD in Kazakhstan, given the limited and primarily descriptive nature of the existing research.
Conclusions: Our review underscores the increasing incidence of inflammatory bowel disease (IBD) in Kazakhstan, highlighting significant challenges in understanding its clinical and pathogenetic aspects. Despite advances in diagnostics and therapies, the precise etiology of IBD remains unclear. The complexity of diagnosing and distinguishing between ulcerative colitis and Crohn's disease, along with inconsistent markers for mucosal healing, emphasizes the need for more standardized diagnostic criteria. Large-scale studies with rigorous methodologies are crucial to advancing our understanding of IBD and improving treatment strategies. Addressing these research gaps is essential for enhancing healthcare and patient outcomes in the region.
Japparkulova Aigerim Bugenbaevna - Faculty of Postgraduate Medical Education, Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, Kazakhstan; E-mail: aigerim.japparkulova@ayu.edu.kz; Phone: +7 702 883 8210; ORCID 0009-0006-8841-2051
Abilov Talgar Satybayuly - Candidate of Medical Sciences, Department of Microbiology, Virology and Immunology, Faculty of Medicine, Rector of Marat Ospanov West Kazakhstan Medical University, Aktobe, Kazakhstan; E-mail: abilovtalgar@gmail.com; Phone: +7 702 227 2813; ORCID 0009-0001-0390-0966
Nursultan Nurdinov Seisenbaiuly - PhD, Senior Lecturer of «Fundamental Medical Sciences» department, Khoja Akhmet Yassawi International Kazakh-Turkish University, E-mail: nursultan.nurdinov@ayu.edu.kz, Phone: +77053787891; ORCID 0000-0001-5341-7211
Aimakhanov Maksat Sakenuly - Senior Lecturer of «Fundamental Sciences» department; Khoja Akhmet Yassawi International Kazakh-Turkish University; E-mail: maksat.aimakhanov@ayu.edu.kz; Phone: +77785356852; ORCID 0000-0002-3295-3493
Nuskabaeva Gulnaz Orazbekovna - Candidate of medical sciences, associate professor, Dean of the «Faculty of Medicine», Khoja Akhmet Yassawi International Kazakh-Turkish University; E-mail: nuskabayeva.gulnaz@ayu.edu.kz; Phone: +77052853131; ORCID 0000-0003-2139-3221
Sadykova Karlygash Zharylkasynovna - PhD, head of «Special clinic subjects» department; Khoja Akhmet Yassawi International Kazakh-Turkish University; E-mail: karlygash.sadykova@ayu.edu.kz; Phone: +77077316476; ORCID 0000-0002-9120-8565
Tuleshova Elmira Zhanbirbayevna - Candidate of Chemical Sciences, Associate Professor of «Fundamental Medical Sciences» department; Khoja Akhmet Yassawi International Kazakh-Turkish University; E-mail: elmira.tuleshova@ayu.edu.kz; Phone: +7 778 176 5176; ORCID 0000-0003-2249-9570
Tastemirova Arailym Berikkyzy - Teacher of Biology, Department of Biology, "Nomad School" innovative school-lyceum, Turkestan, Kazakhstan; E-mail: arailymtastemirovaa@gmail.com; Phone: +77053647498; ORCID 0009-0008-2113-7459
1. Flynn S, Eisenstein S. Inflammatory Bowel Disease Presentation and Diagnosis. Surg Clin North Am. 2019;99(6):1051-1062.
2. M’koma A. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Med. 2022;58(5):567. doi:10.3390/medicina58050567
3. M’Koma A. Clinical Diagnosis and Phar-maceutical Management of Inflammatory Bowel Disease. Med Res Arch. 2023;11(1):10.18103/mra.v11i1.3135. doi:10.18103/mra.v11i1.3135
4. Ng S, Shi H, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-2778. doi:10.1016/S0140-6736(17)32448-0
5. Ng S, Kaplan G, Tang W, et al. Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific. Am J Gastroenterol. 2019;114(1):107-115. doi:10.1038/s41395-018-0233-2
6. Hodges P, Kelly P. Inflammatory bowel disease in Africa: what is the current state of knowledge? Int Health. 202. Int Heal. 2020;12(3):222-230.
7. Quaresma A., Kaplan G., Kotze P. The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil. Curr Opin Gastroenterol 2019 Jul;35(4). 2019;35(4):259-264.
8. Kaibullayeva J, Ualiyeva A, Oshibayeva A, Dushpanova A, Marshall JK. Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study. Intest Res. 2020;18(4):430-437. doi:10.5217/ir.2019.00099
9. Kayali S, Fantasia S, Gaiani F, Cavallaro LG, De’Angelis GL, Laghi L. NOD2 and Crohn’s Disease Clinical Practice: From Epidemiology to Diagnosis and Therapy, Rewired. Inflamm Bowel Dis. 2025;31(2):552-562. doi:10.1093/ibd/izae075
10. Jarmakiewicz-Czaja S, Zielińska M, Sokal A, Filip R. Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update. Genes (Basel). 2022;13(12):2388. doi:10.3390/genes13122388
11. Guo A, Ludvigsson J, Brantsæter AL, et al. Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts. Gut. 2024;73(4):590-600. doi:10.1136/gutjnl-2023-330971
12. Ananthakrishnan AN. Environmental Risk Factors for Inflammatory Bowel Diseases: A Review. Dig Dis Sci. 2015;60(2):290-298. doi:10.1007/s10620-014-3350-9
13. Chhibba T, Gros B, King JA, et al. Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health. J Crohn’s Colitis. 2025;19(4). doi:10.1093/ecco-jcc/jjaf042
14. Kordjazy N, Haj-Mirzaian A, Haj-Mirzaian A, et al. Role of toll-like receptors in inflammatory bowel disease. Pharmacol Res. 2018;(129):204-215.
15. Abubakirova E., Stashkevich D., E.L I. Polymorphism of the genes of toll-like receptors-4 and -9 in patients with nonspecific ulcerative colitis and irritable bowel syndrome of the Russian population of the Chelyabinsk region. Sci Methodol Electron J “Concept.” 2017;39:3221-3225.
16. Lu Y, Li X, Liu S, Zhang Y, Zhang D. Toll-like Receptors and Inflammatory Bowel Disease. Front Immunol. 2018;9(72):1-9.
17. Cheng Y, Zhu Y, Huang X, Zhang W, Han Z, Liu S. Association between TLR2 and TLR4 Gene Polymorphisms and the Susceptibility to Inflammatory Bowel Disease: A Meta-Analysis. Boone DL, ed. PLoS One. 2015;10(5):e0126803. doi:10.1371/journal.pone.0126803
18. Zarzosa-Moreno D, Avalos-Gómez C, Ramírez-Texcalco LS, et al. Lactoferrin and Its Derived Peptides: An Alternative for Combating Virulence Mechanisms Developed by Pathogens. Molecules. 2020;25(24):5763. doi:10.3390/molecules25245763
19. Limpias Kamiya KJL, Hosoe N, Hayashi Y, et al. Video capsule endoscopy in inflammatory bowel disease. DEN Open. 2022;2(1):e26. doi:10.1002/deo2.26
20. Kim K. Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice. Clin Endosc. 2022;55(4):480-488.
21. Djansugurova L, Zhunussova G, Khussainova E, et al. Association of DCC, MLH1, GSTT1, GSTM1, and TP53 gene polymorphisms with colorectal cancer in Kazakhstan. Tumour Biol. 2015;36(1):279-89. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed16&NEWS=N&AN=71609246
22. Dai C, Jiang M, Sun MJ, Cao Q. Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity. J Clin Gastroenterol. 2020;54(6):545-553. doi:10.1097/MCG.0000000000001212
23. Pardali EC, Gkouvi A, Gkouskou KK, et al. Autoimmune protocol diet: A personalized elimination diet for patients with autoimmune diseases. Metab Open. 2025;25:100342. doi:10.1016/j.metop.2024.100342
24. Campbell DE, Mehr S, Moscatelli OG, Anderson RP, Tye-Din JA. Immune therapies in coeliac disease and food allergies: Advances, challenges, and opportunities. Semin Immunol. 2025;78:101960. doi:10.1016/j.smim.2025.101960
25. Rakhmetova V, Orazbayeva A. Stem cells therapy in inflammatory bowel disease. J Clin Med Kazakhstan. 2017;4(46):6-10.
26. Ponomareva E., Voevodina Y. Нормализация микрофлоры кишечника пробиотическими препаратами. Наука сегодня задачи и пути их решения Материалы международной научно-практической конференции В 2-х частях, Вологда. 2018;1(1):122-125.
27. Duryee MJ, Ahmad R, Eichele DD, et al. Identification of Immunoglobulin G Autoantibody Against Malondialdehyde-Acetaldehyde Adducts as a Novel Serological Biomarker for Ulcerative Colitis. Clin Transl Gastroenterol. 2022;13(4):e00469. doi:10.14309/ctg.0000000000000469
28. Lee SH, Kwon J eun, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16(1):26. doi:10.5217/ir.2018.16.1.26
29. Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med. 2021;8(765474). doi:10.3389/fmed.2021.765474
30. Abraham B, Quigley E. Antibiotics and probiotics in inflammatory bowel disease: when to use them? Front Gastroenterol. 2020;11(1):62-69.
31. Wang Y, Zhang R, Mao R, Li X. Inflammatory bowel disease cross‐sectional imaging: What’s new? United Eur Gastroenterol J. 2022;10(10):1179-1193. doi:10.1002/ueg2.12343
32. Vrabie R, Kane S. Noninvasive markers of disease activity in inflammatory bowel disease. Gastroenterol Hepatol. 2014;10(9):576-584.
33. Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. Biomarkers in inflammatory bowel disease: a practical guide. Therap Adv Gastroenterol. 2024;17. doi:10.1177/17562848241251600
34. Cantoro L, Monterubbianesi R, Falasco G, et al. The Earlier You Find, the Better You Treat: Red Flags for Early Diagnosis of Inflammatory Bowel Disease. Diagnostics. 2023;13(20):3183. doi:10.3390/diagnostics13203183
35. Revés J, Fernandez-Clotet A, Ordás I, et al. Early Biological Therapy Within 12 Months of Diagnosis Leads to Higher Transmural Healing Rates in Crohn’s Disease. Clin Gastroenterol Hepatol. 2025;23(7):1194-1203.e2. doi:10.1016/j.cgh.2024.07.034
36. Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021;161(1):47-65. doi:10.1053/j.gastro.2021.04.063
37. Moein S, Qujeq D, Vaghari Tabari M, Kashifard M, Hajian-Tilaki K. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Casp J Intern Med. 2017;8(3):178-182. doi:10.22088/cjim.8.3.178
38. Ünal K. Diagnostic accuracy of the combination of fecal calprotectin and occult blood tests in inflammatory bowel disease. Int J Med Biochem. 2025;8(1):32-38. doi:10.14744/ijmb.2024.30085
39. Kan YM, Chu SY, Loo CK. Diagnostic accuracy of fecal calprotectin in predicting significant gastrointestinal diseases. JGH Open. 2021;5(6):647-652. doi:10.1002/jgh3.12548
40. An Y, Prince D, Gardiner F, et al. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta‐analysis. Med J Aust. 2019;211(10):461-467. doi:10.5694/mja2.50384
41. Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta. 2020;510:556-565. doi:10.1016/j.cca.2020.08.025
42. Shi JT, Chen N, Xu J, et al. Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med. 2023;12(3):1206. doi:10.3390/jcm12031206
43. Nikitin А, Matyukhin A, Mordasova V, Latysheva M. The significance of calprotectin for the evaluation of activity of inflammation in ulcerative colitis. Klin med. 2016;94(7):540-543. doi:DOI 10.18821/0023-2149-2016-94-7-540-543
44. Zaletova N. Comparative assessment of clinical, laboratory and instrumental data in the diagnosis of inflammatory bowel diseases in children. Exp Clin Gastroenterol. 2015;2:89-99.
45. Zinkevich, O. D., Mukhametova, D. D., Abdulganieva DI, Safina NA, Koporulina MO, Odintsova AH. Fecal gelatinase-associated lipocalin (ngal) is a surrogate marker of inflammation in inflammatory bowel diseases /Желатиназо-ассоциированный липокалин (ngal) фекалий - суррогатный маркер воспаления при воспалительных заболеваниях кишечника. Exp Clin Gastroenterol. 2014;10(110):22-27.
46. Orlinskaya NY. The importance of morphological studies in inflammatory bowel diseases in children. Med Alm. 2018;3:47-48.
47. Kessaeva I., Kaloeva Z., Barycheva L., Golubeva M. Informative value of fecal calprotectin in diagnostics of acute intestinal infections in children. Fundam Res. 2015;1:87-91.
48. Maleeva N. Clinical manifestation of celiac disease in the age aspect. Russ Bull Perinatol Pediatr. 2016;2:3-6.
49. Borowitz SM. The epidemiology of inflammatory bowel disease: Clues to pathogenesis? Front Pediatr. 2023;10. doi:10.3389/fped.2022.1103713
50. Saez A, Herrero-Fernandez B, Gomez-Bris R, Sánchez-Martinez H, Gonzalez-Granado J. Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int J Mol. Int J Mol Sci 2. 2023;24(2):1526.
51. Al-Qahtani A, Alhamlan F, Al-Qahtani A. Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review. Trop Med Infect Dis. 2024;9(1):13.
52. Garcia NM, Cohen NA, Rubin DT. Treat‐to‐target and sequencing therapies in Crohn’s disease. United Eur Gastroenterol J. 2022;10(10):1121-1128. doi:10.1002/ueg2.12336
53. Jang D, Lee A, Shin H, et al. The role of tumor necrosis factor alpha (Tnf-α) in autoimmune disease and current tnf-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):1-16. doi:10.3390/ijms22052719
54. Zhetpisbayeva K., Adrisova K., Zhetpisbaev B., Imanbayeva N., K.M A. Immunological aspects of the pathogenesis of ulcerant colitis. Nauk i Zdr [Science Heal. 2023;25(4):118-126. doi:doi 10.34689/SH.2023.25.4.014
55. Ma S, Zhang J, Liu H, Li S, Wang Q. The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease. Front Cell Dev Biol. 2022;26(10):896591. doi:10.3389/fcell.2022.896591
56. Ge L, Liu S, Li S, et al. Psychological stress in inflammatory bowel disease: Psychoneuroimmunological insights into bidirectional gut–brain communications. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.1016578
57. Huynh D, Khaing MM. Exploring the Interconnections of Functional Gut Disorders and Inflammatory Bowel Disease: A Narrative Review Article. Cureus. Published online February 6, 2024. doi:10.7759/cureus.53699
58. Veauthier B, Hornecker J. Crohn’s disease: Diagnosis and management. Am Fam Physician. 2018;1(98):661-669.
59. Belei O, Basaca D., Olariu L, et al. The Interaction between Stress and Inflammatory Bowel Disease in Pediatric and Adult Patients. J Clin Med. 2024;13(5):1361-1400. doi:10.3390/jcm13051361
60. Anand R, George AT, Rubin DT, Spiegel BMR, Bernstein CN. The role of virtual reality in managing inflammatory bowel disease: a novel approach to bridging mental and physical health. J Can Assoc Gastroenterol. 2025;8(Supplement_2):S15-S20. doi:10.1093/jcag/gwae060
Количество просмотров: 162
Категория статей:
Обзор литературы
Библиографическая ссылка
Japparkulova A., Abilov T., Nurdinov N., Aimakhanov M., Nuskabayeva G., Sadykova K., Tuleshova E., Tastemirova A. Clinical and pathogenetic features of inflammatory bowel diseases: а literature review // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (2), pp. 188-197. doi 10.34689/SH.2024.27.2.021Похожие публикации:
RADIATION EXPOSURE IN THE SEMIPALATINSK REGION: TRANSGENERATIONAL RISKS AND DOSIMETRY APPROACHES
TRENDS AND PATTERNS OF MALE REPRODUCTIVE SYSTEM DISEASES IN THE CONTEXT OF MEDICAL AND DEMOGRAPHIC INDICATORS. LITERATURE REVIEW
INFECTIOUS COMPLICATIONS OF UROLOGICAL INTERVENTIONS FOR UROLITHIASIS. LITERATURE REVIEW
PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AS A GLOBAL HEALTH PROBLEM
THE QUALITY OF LIFE OF PATIENTS WITH COPD. LITERATURE REVIEW